Innovation and Technology
Medical institutions that are leading the transition to personalized medicine need innovative programs that are designed to eliminate the traditional boundaries separating clinical care and research environments. The Charles Bronfman Institute for Personalized Medicine (IPM) has developed and implemented visionary programs that introduce patients with translational genomics and data-driven personalized medicine research, to evaluate the utility of genomics and personalized medicine in clinical care. The BioMe Biobank Platform consents patients in clinical care to enable them to participate in future personalized medicine research projects. The institute aims to enroll 100,000 patients in its programs. The CLIPMERGE Program enables the integration and evaluation of genomic and clinical data for personalized clinical decision support.